A. Mức độ giảm nguy cơ đột quỵ với sự gia tăng aspirin với liều tăng lên đến 650 mg mỗi ngày. B. Aspirin tăng cường hoạt động của cyclooxygenase. C. Aspirin ngăn chặn việc sản xuất thromboxane A2, một hoạt hóa tiểu cầu và co mạch. D. Aspirin độc tính là không rõ ràng phụ thuộc vào liều. | PHARMACOLOGY QUESTIONS 19 57. Tissue plasminogen activator t-PA A. Is a strong activator of plasminogen. B. Is a poor activator of plasminogen unless exposed to fibrin. C. Is cleared mainly by the kidney. D. Is less expensive than streptokinase. 58. Aminocaproic acid Amicar A. Is a procoagulant substance. B. Is an inhibitor of fibrinolysis. C. Is a useful therapy to prevent rebleeding in patients with subarachnoid hemorrhage. D. Is proven to be an effective treatment to reduce bleeding during surgery. 59. Which statement about aspirin is true A. The degree of stroke risk reduction with aspirin increases with increasing dose up to 650 mg daily. B. Aspirin enhances the activity of cyclooxygenase. C. Aspirin blocks the production of thromboxane A2 a platelet activator and vasoconstrictor. D. Aspirin toxicity is not clearly dose-dependent. 60. Dipyridamole Persantine A. Has mild vasoconstrictor effect in high doses. B. Inhibits platelets by inhibiting cyclooxygenase. C. Decreases the intracellular concentration of cyclic adenosine monophosphate cAMP . D. Blocks the uptake of adenosine. 61. Ticlopidine Ticlid and clopidogrel Plavix are A. Similar in toxicity profiles. B. Rapidly absorbed resulting in rapid therapeutic effect. C. Thienopyridine agents closely related in chemical structure. D. Platelet inhibitors and vasodilators. 20 PHARMACOLOGY QUESTIONS 62. Abciximab ReoPro A. Inhibits platelet activation induced by thrombin collagen or thromboxane A2. B. Inhibits platelet activation by promoting the action of von Willebrand factor. C. Can be administered orally or parenterally. D. Has a t1 2 of 2 hours following IV administration. E. Is extracted from porcine intestine. 63. Eptifibatide Integrilin is A. A monoclonal antibody that is directed toward the platelet glycoprotein IIb IIIa receptor. B. A peptide that inhibits platelet activation by interaction with the vitronectin receptor on platelets. C. An antibody that inhibits platelets by binding the collagen receptor.
